ATF7IP-Mediated Stabilization of the Histone Methyltransferase SETDB1 Is Essential for Heterochromatin Formation by the HUSH Complex by Timms, Richard et al.
ReportATF7IP-Mediated Stabilization of the Histone
Methyltransferase SETDB1 Is Essential for
Heterochromatin Formation by the HUSH ComplexGraphical AbstractHighlightsd The SETDB1-interacting partner ATF7IP is critical for HUSH-
mediated silencing
d ATF7IP shields SETDB1 from proteasomal degradation in the
nucleus
d Loss of ATF7IP phenocopies loss of SETDB1 in genome-wide
assaysTimms et al., 2016, Cell Reports 17, 653–659
October 11, 2016 ª 2016 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.09.050Authors
Richard T. Timms,
Iva A. Tchasovnikarova, Robin Antrobus,
Gordon Dougan, Paul J. Lehner
Correspondence
pjl30@cam.ac.uk
In Brief
The histone lysine methyltransferase
SETDB1 is a central chromatin regulator,
but the function of its binding partner
ATF7IP has remained enigmatic. Timms
et al. find that ATF7IP plays an essential
role in heterochromatin formation by
shielding SETDB1 from proteasomal
degradation in the nucleus.Accession NumbersGSE86814
Cell Reports
ReportATF7IP-Mediated Stabilization of the Histone
Methyltransferase SETDB1 Is Essential
for Heterochromatin Formation by the HUSH Complex
Richard T. Timms,1,3 Iva A. Tchasovnikarova,1,3 Robin Antrobus,1 Gordon Dougan,2 and Paul J. Lehner1,4,*
1Department of Medicine, Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK
2Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK
3Co-first author
4Lead Contact
*Correspondence: pjl30@cam.ac.uk
http://dx.doi.org/10.1016/j.celrep.2016.09.050SUMMARY
The histone methyltransferase SETDB1 plays a cen-
tral role in repressive chromatin processes, but
the functional requirement for its binding partner
ATF7IP has remained enigmatic. Here, we show
that ATF7IP is essential for SETDB1 stability: nuclear
SETDB1 protein is degraded by the proteasome
upon ablation of ATF7IP. As a result, ATF7IP is crit-
ical for repression that requires H3K9 trimethylation
by SETDB1, including transgene silencing by the
HUSH complex. Furthermore, we show that loss of
ATF7IP phenocopies loss of SETDB1 in genome-
wide assays. ATF7IP and SETDB1 knockout cells
exhibit near-identical defects in the global deposi-
tion of H3K9me3, which results in similar dysregula-
tion of the transcriptome. Overall, these data identify
a critical functional role for ATF7IP in heterochro-
matin formation by regulating SETDB1 abundance
in the nucleus.
INTRODUCTION
The post-translational modification of histone proteins is a
critical mechanism to control chromatin architecture and gene
expression in eukaryotic cells (Kouzarides, 2007). SETDB1
(also known as ESET) is a key enzyme responsible for methyl-
ation of lysine 9 of histone H3 (H3K9me), which is a hallmark of
repressed chromatin (Becker et al., 2016). However, four addi-
tional methyltransferases (G9a, GLP, SUV39H1, and SUV39H2)
are also known to target H3K9, raising the question as to how
the activities of these enzymes are coordinately regulated to
generate the required distribution of H3K9 methylation across
the genome (Mozzetta et al., 2015). The importance of correct
regulation of SETDB1 is underscored by the oncogenic potential
of SETDB1 overexpression, with amplification of SETDB1 impli-
cated in the progression of malignant melanoma (Ceol et al.,
2011) and cancers of the prostate (Sun et al., 2014), liver (Fei
et al., 2015; Wong et al., 2016), and lung (Rodriguez-Paredes
et al., 2014; Sun et al., 2015).Cell
This is an open access article undBinding partners provide onemechanism to regulate the activ-
ity of these methyltransferases. ATF7IP (also known as MCAF1
or hAM) has been recognized as a SETDB1-interacting protein
for more than a decade (Fujita et al., 2003; Wang et al., 2003),
but its functional role has remained elusive. Initially, ATF7IP
was proposed to act as a directmodulator of the catalytic activity
of SETDB1, with mAM, the murine homolog of ATF7IP, shown
to stimulate the catalytic activity of murine SETDB1 in vitro
and promote the efficient conversion of di-methyl H3K9 to the
tri-methylated state (Wang et al., 2003). However, a recent study
found little effect of human ATF7IP on the in vitro catalytic activity
of human SETDB1 (Basavapathruni et al., 2016), leading to the
suggestion that the in vivo role of ATF7IP could be to regulate
the spatial or temporal recruitment of SETDB1 to target sites
on chromatin (Basavapathruni et al., 2016; Koch et al., 2009).
Previously, we identified the Human Silencing Hub (HUSH)
complex as a regulator of heterochromatin formation inmamma-
lian cells (Tchasovnikarova et al., 2015). HUSH comprises
three proteins, TASOR, MPP8, and Periphilin, which together re-
cruit SETDB1 to deposit H3K9me3 and mediate transcriptional
repression at heterochromatic loci (Tchasovnikarova et al.,
2015). While searching for proteins required alongside SETDB1,
we identified an essential role for ATF7IP in HUSH complex func-
tion. Here we clarify the function of ATF7IP, showing that it plays
a critical role in SETDB1-mediated H3K9me3 deposition by
shielding SETDB1 from proteasomal degradation in the nucleus.RESULTS
The SETDB1-Interacting Partner ATF7IP Is Essential for
Epigenetic Silencing by the HUSH Complex
We took a proteomic approach to identify proteins that act
alongside SETDB1 in HUSH-mediated epigenetic silencing.
Immunoprecipitation of SETDB1 from the nuclei of HeLa cells
followed by mass spectrometry (Figure 1A) identified ATF7IP
as the top candidate that was not present in the control sample
(Figure 1B; Table S1). We were readily able to validate the inter-
action between SETDB1 and ATF7IP in a reciprocal co-immuno-
precipitation experiment (Figure 1C), a finding that is consistent
with a number of previous reports (Ichimura et al., 2005; Koch
et al., 2009; Wang et al., 2003). Because H3K9me3 depositionReports 17, 653–659, October 11, 2016 ª 2016 The Author(s). 653
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Figure 1. The SETDB1-Interacting Protein ATF7IP Is Critical for HUSH-Mediated Epigenetic Repression
(A–C) SETDB1 binds ATF7IP. Immunoprecipitation of SETDB1 from HeLa nuclear lysates followed by mass spectrometry (A) identified ATF7IP as the most
significantly enriched co-immunoprecipitating protein (B); immunoprecipitation of ATF7IP also pulled down SETDB1 (C).
(D) ATF7IP is critical for transgene silencing by the HUSH complex. CRISPR/Cas9-mediated disruption of ATF7IP resulted in the reactivation of a HUSH-
repressed GFP reporter.
(E) Depletion of ATF7IP results in reactivation of a silent GFP reporter construct. A HeLa clone harboring a HUSH-repressed GFP reporter was transduced with
lentiviral vectors expressing either a control shRNA or shRNAs targeting ATF7IP, and derepression of the GFP reporter construct was assayed by flow cytometry.
(F) Knockout of ATF7IP results in derepression of HUSH-repressed GFP reporter constructs in KBM7 cells. A polyclonal population of KBM7 cells harboring
HUSH-repressed GFP reporter constructs was transduced sequentially with lentiviral vectors expressing Cas9 and single guide RNAs (sgRNAs) targeting
ATF7IP, and depression of the GFP reporter constructs was monitored by flow cytometry.
See also Figures S1 and S2.by SETDB1 is critical for HUSH-mediated transgene repression
(Tchasovnikarova et al., 2015), we examined whether ATF7IP
was also essential for this process. We ablated ATF7IP function
in a HeLa clone harboring a HUSH-repressed GFP reporter
construct (Tchasovnikarova et al., 2015), through either short
hairpin RNA (shRNA)-mediated knockdown or CRISPR/Cas9-
mediated gene disruption, and examined the impact on reporter
silencing by flow cytometry. In both cases, loss of ATF7IP re-
sulted in the abrogation of HUSH-mediated silencing and
derepression of the reporter construct (Figures 1D and 1E).
Similar results were observed in a polyclonal KBM7 reporter
line harboring HUSH-repressed GFP transgenes (Figure 1F).
Therefore, ATF7IP is critical for HUSH-mediated transgene
silencing.
ATF7IP Protects SETDB1 from Proteasomal
Degradation in the Nucleus
To characterize the functional role of ATF7IP, we generated
ATF7IP-deficient HeLa clones through CRISPR/Cas9-mediated
gene disruption (Figures S1A and S1B). Our antibody against
ATF7IP was not capable of recognizing its epitope in direct654 Cell Reports 17, 653–659, October 11, 2016immunoblot analysis (Figure S1C), but we were able to validate
an absence of ATF7IP protein by immunoprecipitation of ATF7IP
followed by immunoblot (Figure S1D). The overall abundance of
SETDB1 was not significantly affected in the ATF7IP knockout
clones (Figure 2A), but, strikingly, SETDB1 was lost from the nu-
cleus in the absence of ATF7IP (Figure 2B). We observed a
similar outcome following shRNA-mediated depletion of ATF7IP
(Figures S1E and S1F). This result suggested two potential roles
for ATF7IP that are notmutually exclusive: import of SETDB1 into
the nucleus and stabilization of SETDB1 in the nucleus. Treat-
ment of ATF7IP knockout cells with the proteasome inhibitor
bortezomib (Velcade) resulted in marked recovery of SETDB1
protein levels in the nucleus (Figure 2C), demonstrating that
SETDB1 was able to enter the nucleus in the absence of ATF7IP
but in doing so became a substrate for proteasomal degradation
(Figure 2C). Therefore, ATF7IP stabilizes SETDB1 in the nucleus.
We also examined the fate of ATF7IP in the absence
of SETDB1. In SETDB1 knockout clones generated through
CRISPR/Cas9-mediated gene disruption (Figure S2), the levels
of ATF7IP protein were severely reduced (Figure 2D). In wild-
type cells, ATF7IP was present almost exclusively in the nuclear
Figure 2. ATF7IP Shields SETDB1 from Proteasomal Degradation in the Nucleus
(A and B) Loss of ATF7IP abolishes the nuclear pool of SETDB1. The overall abundance of SETDB1 protein was not significantly affected in three independent
ATF7IP knockout clones as assessed by immunoblot (A), but subcellular fractionation revealed a loss of SETDB1 from the nuclear fractions (B).
(C) ATF7IP protects SETDB1 from proteasomal degradation in the nucleus. Treatment of ATF7IP knockout cells with the proteasome inhibitor bortezomib (20 nM
for 40 hr) recovered SETDB1 levels in the nuclear fraction.
(D and E) ATF7IP is destabilized in the absence of SETDB1. Loss of SETDB1 results in destabilization of ATF7IP (D), which can be recovered upon treatment with
bortezomib (E).
See also Figure S2.fraction, and bortezomib treatment of SETDB1 knockout cells
was able to partially rescue nuclear ATF7IP levels (Figure 2E).
Therefore, ATF7IP and nuclear SETDB1 are responsible for
each other’s stability.
Loss of ATF7IP Phenocopies that of SETDB1 Deletion
This reciprocal relationship between SETDB1 and ATF7IP pre-
dicts that the loss of ATF7IP should phenocopy that of SETDB1
deletion. We tested this hypothesis in a range of experimental
systems. First, using competitive growth assays, we demon-
strated that knockout of ATF7IP and SETDB1 had a similarly
detrimental effect on the growth of HeLa cells (Figure S3A).
In contrast to HeLa cells lacking the HUSH components TASOR
or MPP8, cells lacking either ATF7IP or SETDB1 (as marked
by GFP reporter expression) were progressively diluted from
the population upon co-culture with the parental wild-type cells
(Figure S3A).
In murine embryonic stem cells (mESCs), retroelements are
epigenetically repressed through H3K9me3 in a process
involving the KAP1-dependent recruitment of SETDB1 (Matsui
et al., 2010; Rowe et al., 2010). We found that, as observed
upon depletion of SETDB1, shRNA-mediated knockdown of
ATF7IP in mESCs resulted in depression of an exogenous viral
GFP reporter (Figure S3B). This finding is consistent with the re-
sults of a genome-wide screen to identify viral silencing factors
in mESCs, which was published during the preparation of this
manuscript (Yang et al., 2015).
Previously, we showed that SETDB1 deletion in HeLa cells re-
sults in genome-wide loss of H3K9me3 across thousands of loci
(Tchasovnikarova et al., 2015). To determine whether this effect
was mirrored upon disruption of ATF7IP, we used chromatinimmunoprecipitation followed by deep sequencing (ChIP-seq)
to compare the distribution of H3K9me3 in SETDB1-null and
ATF7IP-null clones. The distribution of H3K9me3 was almost
identical in each case, with dramatic changes in H3K9me3 levels
observed across large segments of the genome (Figures 3A–3C).
Considering the genome as a series of 1 kb windows, this exper-
iment identified 207,713 loci showing a >3-fold decrease in
H3K9me3 levels in SETDB1 knockout cells when compared to
the wild-type parental cell line; of these loci, 99.3% also showed
a decrease in H3K9me3 in ATF7IP knockout cells. Similarly, of
the 166,700 loci exhibiting a >3-fold loss of H3K9me3 in ATF7IP
knockout cells, 99.7% displayed a decrease in H3K9me3 levels
in SETDB1 knockout cells. The overall concordance between
the two knockout samples was extremely high (Spearman’s
rank correlation coefficient r = 0.88) (Figure 3D), andwe validated
these findings at several example loci by ChIP-qPCR in an inde-
pendent experiment (Figure 3E). Previously we identified 918
genomic loci at which knockout of either of the HUSH subunits
TASOR, MPP8, or Periphilin resulted in a significant decrease in
H3K9me3 (Tchasovnikarova et al., 2015); at 98% of these loci,
we also observed a decrease in H3K9me3 upon knockout of
either SETDB1 or ATF7IP, with90% of the loci in each case ex-
hibiting a decrease >3-fold (Figure S3C). One of the most striking
effects of SETDB1 or ATF7IP depletion was loss of H3K9me3
across genes encoding zinc-finger proteins (Figures 3C and 3F).
The deposition of H3K9me3 across the bodies of these genes is
dependent on the function of the SETDB1-ATF7IP complex (Fig-
ure 3G), with the magnitude of the effect upon knockout of either
component showing high concordance (Figure 3H).
Finally, we compared the global effects of deletion of
SETDB1 and ATF7IP on the transcriptome by carrying out RNACell Reports 17, 653–659, October 11, 2016 655
Figure 3. H3K9me3 Loss across the Genome Is Similar upon Deletion of ATF7IP or SETDB1
(A–D) The distribution of H3K9me3 in wild-type, ATF7IP knockout, and SETDB1 knockout cells was assessed by ChIP-seq analysis. Three example loci are
shown (A–C); near-identical profiles were observed in the ATF7IP and SETDB1 knockout cells (D).
(E–H) Loss of ATF7IP and SETDB1 results in loss of H3K9me3 across zinc-finger genes. Validation of the ChIP-seq results by ChIP-qPCR at three example KRAB-
ZNF gene loci (E). A near-total loss of H3K9me3 was observed across zinc-finger genes in the knockout cells (F and G), and the magnitude of this effect was
similar in the ATF7IP and SETDB1 knockout samples (H). The error bars in (E) represent the SD of three qPCR technical replicates.
See also Figures S3 and S4.sequencing (RNA-seq) analysis in the knockout clones (Fig-
ure 4A). Depletion of either SETDB1 or ATF7IP resulted in
significantly altered expression of >1,000 genes in each case
compared to wild-type cells (Figures 4B, 4C, and S4A). However,
only a handful of genes (n = 9, p < 0.05 DEseq) exhibited differ-
ential expression when comparing the transcriptome of SETDB1
knockout cells to that of ATF7IP knockout cells (Figures 4D and
4E). Of particular interest were the genes upregulated in SETDB1
and ATF7IP knockout cells compared to wild-type cells. The
DAVID functional annotation tool (Huang et al., 2009) identified
two classes of derepressed genes in each case: zinc-finger
genes and histone genes (Figure S4B). We focused on those
genes that were either not expressed or weakly expressed in
wild-type cells but became strongly expressed in the knockout
cells; this generated a common set of 43 genes (Figure S4C).
In support of the idea that the increased expression of these
genes was due to loss of H3K9 methylation in the absence
of SETDB1 and ATF7IP, H3K9me3 levels were substantially
reduced across these genes in both sets of knockout cells656 Cell Reports 17, 653–659, October 11, 2016(Figures S4D and S4E), concomitant with the increase in tran-
scription (Figure S4F). Altogether, both the ChIP-seq and
the RNA-seq datasets supported a functional co-dependence
between SETDB1 and ATF7IP.
DISCUSSION
The goal of this study was to clarify the functional role of the
SETDB1-binding partner ATF7IP. We found that in the absence
of ATF7IP, SETDB1 was not stable in the nucleus and was
subject to proteasomal degradation. Overall, these data explain
why ATF7IP is critical for transgene silencing by the HUSH com-
plex and other repressive epigenetic processes that require
H3K9me3 deposition by SETDB1.
Although stabilization of SETDB1 is clearly a central function
for ATF7IP, it seems unlikely that this is its only role. For example,
the C-terminal fibronectin type-III domain of ATF7IP has been
shown to bind the methyl-DNA binding protein MBD1 (Ichimura
et al., 2005), with functional roles forMBD1 and ATF7IP identified
Figure 4. Deletion of ATF7IP Mirrors the
Effect of SETDB1 Deletion on the Tran-
scriptome
(A) Schematic representation of the RNA-seq
experiment.
(B–E) Loss of ATF7IP and SETDB1 results in
highly similar effects on the transcriptome. The
colored dots represent genes exhibiting signifi-
cantly altered expression (see Experimental
Procedures) in ATF7IP knockout cells (green)
or SETDB1 knockout cells (yellow) compared to
wild-type cells (B and C); these genes are affected
similarly in both knockout cells, because they lie
in the center of the distribution when comparing
ATF7IP knockout cells to SETDB1 knockout
cells (D and E).
See also Figure S4.in transcriptional regulation (Waterfield et al., 2014) and X chro-
mosome inactivation (Minkovsky et al., 2014). It remains to
be tested whether MBD1 also plays a critical role alongside
SETDB1 and ATF7IP in HUSH-mediated epigenetic silencing.
SETDB1 does not appear to be an intrinsically unstable pro-
tein, given that it can be recombinantly expressed in isolation
in insect cells (Wang et al., 2003) and is found in the cytosol in
the absence of ATF7IP (Figure 2B). Therefore, it seems likely
that an active degradation process removes unshielded SETDB1
in the nucleus, and an important goal for future work will be to
delineate the degradativemachinery responsible. However, it re-
mains unclear what evolutionary advantage ATF7IP-mediated
regulation of SETDB1 may provide. One possibility is that
modulation of ATF7IP levels can provide dynamic regulation of
SETDB1 methyltransferase activity during development or in
response to specific stimuli. Alternatively, ATF7IP could simply
act as a safety mechanism to prevent SETDB1 overactivity.
Amplification of SETDB1 is heavily implicated in tumorigenesis
(Ceol et al., 2011; Fei et al., 2015; Rodriguez-Paredes et al.,
2014; Sun et al., 2014, 2015;Wong et al., 2016), and upregulationCell Rof ATF7IP has been observed in a num-
ber of tumors (Liu et al., 2009), suggest-
ing that overexpression of SETDB1
could have deleterious effects. Given
that no effective small molecule inhibitors
of SETDB1 catalytic activity have been
developed, our data raise the possibil-
ity that an alternative strategy to inhibit
SETDB1 activity could be to target
ATF7IP. Structural insight would be valu-
able in assessing the feasibility of target-
ing the SETDB1-ATF7IP interface for
therapeutic benefit.
EXPERIMENTAL PROCEDURES
Co-immunoprecipitation and Mass
Spectrometry
HeLa cells were grown in RPMI 1640 supple-
mented with 10% fetal calf serum and penicillin
and streptomycin. Nuclei were extracted with0.1% IGEPAL (Sigma-Aldrich) and then lysed in 1% IGEPAL plus 1:100 benzo-
nase (Sigma-Aldrich). Nuclear lysates were pre-cleared with protein A and
immunoglobulin G (IgG)-sepharose and then incubated with primary antibody
and protein G-coated magnetic beads (Thermo Fisher Scientific) for 2 hr at
4C. Following three washes in lysis buffer, bound proteins were eluted from
the beads in SDS sample buffer. For analysis by mass spectrometry, immuno-
precipitates were first resolved by SDS-PAGE, with each lane cut into four
slices for in-gel digestion. Tryptic peptides were analyzed by liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS), and the raw data were pro-
cessed in Proteome Discoverer v.1.4. Data were searched using Sequest
against the Human Uniprot database (downloaded March 3, 2014; 68,710
sequences).
Subcellular Fractionation
One million HeLa cells were washed twice in PBS and once in Buffer A (10 mM
HEPES, 1.5 mMMgCl2, 10 mM KCl, 0.5 mM DTT, and an EDTA-free protease
inhibitor cocktail tablet; Roche). Cells were then resuspended in Buffer A plus
0.1% (v/v) IGEPAL and incubated on ice for 10 min. The supernatant contain-
ing the cytosolic fraction was collected following centrifugation at 1,4003 g for
4 min at 4C. To isolate the total nuclear fraction, the nuclear pellet was then
lysed in 1% SDS plus 1:100 benzonase (Sigma-Aldrich) for 20 min at room
temperature. For further separation into nucleosolic and chromatin fractions,
the nuclear pellet was resuspended in Buffer B (20 mM HEPES, 1.5 mMeports 17, 653–659, October 11, 2016 657
MgCl2, 300 mM NaCl, 0.5 mM DTT, 25% v/v glycerol, 0.2 mM EDTA, and
an EDTA-free protease inhibitor cocktail tablet) for 10 min on ice. Following
centrifugation at 1,700 3 g for 4 min at 4C, the supernatant contained the
nucleosolic fraction and the insoluble pellet the chromatin fraction. The pellet
was then solubilized in 1% SDS plus 1:100 benzonase.
H3K9me3 ChIP-Seq
HeLa cells were washed once in PBS, resuspended in RPMI growth media,
and then cross-linked for 10 min by the addition of 1% formaldehyde. The
reaction was quenched for 5 min by the addition of glycine to a final con-
centration of 0.125 M, and the cells were lysed in cell lysis buffer (1 mM
HEPES, 85 mM KCl, and 0.5% NP-40). The nuclei were then lysed in nu-
clear lysis buffer (5 mM Tris, 10 mM EDTA, and 1% SDS) and the chromatin
was sheared using a Bioruptor (Diagenode; 20 cycles of 30 s on and 30 s off
on high power) to obtain a mean fragment size of 300 bp. The chromatin
solution was then pre-cleared with protein A sepharose (Sigma-Aldrich),
and the immunoprecipitation reaction was performed overnight using
5 mg of anti-H3K9me3 (Abcam; ab8898) primary antibody and protein A se-
pharose. The beads were washed five times before bound protein-DNA
complexes were eluted with 150 mM NaHCO3 and 1% SDS. Cross-links
were reversed by the addition of 0.3 M NaCl and RNase A, followed by
incubation at 67C for 4 hr. Proteins were removed by the addition of Pro-
teinase K for 2 hr at 45C, and the DNA was purified using a spin column
(QIAGEN PCR purification kit). Illumina sequencing libraries were created
using the NEBNext ChIP-Seq Library Prep Kit (NEB) and sequenced on
a HiSeq 2500 instrument. Reads were aligned to the human genome
(GRCh37) using Bowtie2 and further analyzed using SeqMonk and EaSeq
(Lerdrup et al., 2016).
RNA-Seq
RNA was extracted from three independent ATF7IP and SETDB1 knockout
clones using the miRNEasy kit (QIAGEN) as recommended by the manufac-
turer. Genomic DNA was removed by on-column digestion with DNase I,
and rRNAs were depleted from the resulting samples using the Ribo-Zero
Gold rRNA Removal Kit (Epicenter). Multiplexed Illumina sequencing libraries
were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illu-
mina), and 150 bp paired-end reads were generated on a HiSeq 2500 instru-
ment. Sequencing reads were aligned to the human genome (GRCh37) using
HISAT2. Aligned reads with a MAPQ score > 40 were imported into SeqMonk
and analyzed using the RNA-seq quantitation pipeline, followed by DEseq
analysis. In Figures 4B–4E, the highlighted genes exhibited differential expres-
sion as determined by DEseq (p < 0.05) and passed the Intensity Difference
filter in SeqMonk.
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